Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Dose Determination Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of 13 to 30 years~2. Subjects must be otherwise healthy except for T1DM, and treated for hypothyroidism if present~3. Menstruating women must have negative pregnancy test.~4. Hemoglobin (Hb) more than 12 g/dl~Exclusion Criteria:~1. Having any other chronic condition except hypothyroidism stable on medications~2. On chronic medications that may affect glucose excursions~3. Hemoglobin less than 12 g/dl~4. Positive pregnancy test (based on Urine)~5. Pregnant or lactating mothers~6. Known allergy to Januvia

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Part A (Type: ACTIVE_COMPARATOR): Sitagliptin 25mg
- Part B (Type: ACTIVE_COMPARATOR): Sitagliptin 50mg
- Part C (Type: ACTIVE_COMPARATOR): Sitagliptin 100mg
- Part D (Type: PLACEBO_COMPARATOR): Placebo oral tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).